Halaven Post-Marketing Surveillance (PMS)
This is a PMS to observe the safety profile of Halaven in normal clinical practice setting.
Breast Cancer
Safety of Halaven as a measure of number of participants with adverse events/serious adverse events/adverse drug reactions, Up to 1 year
Tumor response to Halaven treatment, Up to 12 weeks
This is a PMS to observe the safety profile of Halaven in normal clinical practice setting.